A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Amyloidosis
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 18 Sep 2017 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Updated results (data cutoff 23 Jun 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.